Literature DB >> 30106099

Overexpression of miR‑21 is involved in acute monocytic leukemia‑associated angiogenesis by targeting IL‑12.

Xue-Peng He1, Peng Chen1, Kai Yang1, Bing Liu1, Yuan Zhang1, Fang Wang1, Zhi Guo1, Xiao-Dong Liu1, Jin-Xing Lou1, Hui-Ren Chen1.   

Abstract

Angiogenesis is important in pathophysiological processes, including the pathogenesis of acute monocytic leukemia (AML). MicroRNA‑21 (miR‑21) is overexpressed and exhibits oncogenic activity in cancer. However, the biological mechanism underlying the effect of miR‑21 in AML remains to be fully elucidated. In the present study, the expression levels of miR‑21 and vascular endothelial growth factor (VEGF) were determined in 26 patients with AML and 28 healthy individuals. The secretion of VEGF was also measured following the transfection of THP‑1 cells with miR‑21 mimic or inhibitor. The supernatants of the THP‑1 cells, which were transfected with miR‑21 mimic, inhibitor or small interfering RNA (si)VEGF, respectively, were used to incubate human umbilical vein endothelial cells (HUVECs), following which tube formation of the HUVECs was measured. miR‑21 targets were predicted using a biological target prediction website and confirmed using a luciferase assay. The effects of interleukin (IL)‑12 were investigated by examining the tube formation of HUVECs and the secretion of VEGF following recombinant human (rh) IL‑12 pretreatment. The results revealed that miR‑21 and VEGF expression was significantly increased in the peripheral blood monocytes of the patients, compared with the healthy controls. There was negative correlation between the expression of IL‑12 and miR‑21 in the serum of patients with AML. Furthermore, supernatant VEGF levels from the miR‑21 mimic‑transfected THP‑1 cells were increased, whereas a decreasing trend was observed in the miR‑21 inhibitor group. The angiogenic ability of the HUVECs pretreated with supernatant from the THP‑1 cells transfected with miR‑21 mimic was higher, and was lower in THP‑1 cells co‑transfected with miR‑21 mimic and siVEGF, compared with the miR‑21 mimic only group. A luciferase assay demonstrated that IL‑12 was the direct target of miR‑21, and the level of IL‑12 in the supernatant of THP‑1 cells transfected with miR‑21 mimic was increased. IL‑12 pretreatment increased VEGF expression and angiogenic ability in HUVECs. The inactivation of miR‑21 or activation of its target gene may be a potential therapeutic strategy in human AML.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30106099     DOI: 10.3892/mmr.2018.9357

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  5 in total

1.  Tanshinone IIA regulates human AML cell proliferation, cell cycle, and apoptosis through miR-497-5p/AKT3 axis.

Authors:  Zi-Yuan Nie; Ming-Hui Zhao; Bao-Qian Cheng; Rong-Fang Pan; Tian-Rui Wang; Yan Qin; Xue-Jun Zhang
Journal:  Cancer Cell Int       Date:  2020-08-07       Impact factor: 5.722

2.  MicroRNA‑21 contributes to renal cell carcinoma cell invasiveness and angiogenesis via the PDCD4/c‑Jun (AP‑1) signalling pathway.

Authors:  Bo Fan; Yiying Jin; Hongshuo Zhang; Rui Zhao; Man Sun; Mengfan Sun; Xiaoying Yuan; Wei Wang; Xiaogang Wang; Zhiqi Chen; Wankai Liu; Na Yu; Qun Wang; Tingjiao Liu; Xiancheng Li
Journal:  Int J Oncol       Date:  2019-12-02       Impact factor: 5.650

3.  Simvastatin regulates the proliferation, apoptosis, migration and invasion of human acute myeloid leukemia cells via miR-19a-3p/HIF-1α axis.

Authors:  Hua Tian; Tiao Qiang; Jinbo Wang; Li Ji; Bo Li
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

4.  miR-21 antagonist alleviates colitis and angiogenesis via the PTEN/PI3K/AKT pathway in colitis mice induced by TNBS.

Authors:  Xiaoran Xie; Peng Liu; Hao Wu; Huan Li; Yu Tang; Xiong Chen; Canxia Xu; Xiaoming Liu; Guoyu Dai
Journal:  Ann Transl Med       Date:  2022-04

5.  Impact of Bone Marrow miR-21 Expression on Acute Myeloid Leukemia T Lymphocyte Fragility and Dysfunction.

Authors:  Douâa Moussa Agha; Redouane Rouas; Mehdi Najar; Fatima Bouhtit; Hussein Fayyad-Kazan; Laurence Lagneaux; Dominique Bron; Nathalie Meuleman; Philippe Lewalle; Makram Merimi
Journal:  Cells       Date:  2020-09-08       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.